ANAVEX LIFE SCIENCES CORPORATION (AVXL)
Track the next or latest earnings date for ANAVEX LIFE SCIENCES CORPORATION, review consensus estimates, and see cached AI analysis for recent quarterly results.
Recent earnings news
barchart.com · 3 days ago
AeroVironment shares jumped 18.76% after posting strong fiscal Q1 2026 results with revenue of $641.6 million and an adjusted EPS beat.
AVXL Earnings: Latest Report, Earnings Call & Financialspublic.com · February 12, 2025
Following the last earnings report on Feb 9, 2026, AVXL's stock price moved — from — to —.
AeroVironment Stock (AVAV) Opinions on Recent Earnings Surge Amid Legal Concerns | Quiver Quantitativequiverquant.com · 2 days ago
Earnings Surge: AeroVironment reported fiscal first-quarter revenue of $642 million, marking a 133% year-over-year increase, which propelled shares sharply higher in recent sessions. Market participants noted the strong results alongside an adjusted earnings beat as key drivers behind the momentum.
AVXL Stock News Today | Earnings, Events & Price Alertsintellectia.ai · 3 weeks ago
Latest AVXL stock news: earnings reports, major events, and real-time price action alerts. Daily updates on everything moving AVXL stock.
AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committeestocktwits.com · November 10, 2025
On Monday, CHMP included Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13.
Latest earnings date
Time not specified
Fiscal quarter: 2026-03-31
EPS estimate: -$0.07
Revenue estimate: N/A
Market cap: $251.14M
AI earnings summary
Company expects over 3-year cash runway at current burn rate with current balance exceeding $120 million. Management outlined multiple development milestones including regulatory updates for blarcamesine across Alzheimer's, Parkinson's, and Rett syndrome programs, plus advancing ANAVEX3-71 toward pivotal schizophrenia studies.
Sentiment and reaction
Sentiment score: +60.00%
Post-earnings price reaction: +12.34%
EPS
Estimate: -$0.10
Actual: -$0.11
Surprise: -10.00%
Revenue
Estimate: N/A
Actual: N/A
Surprise: N/A
Financial highlights
• Net loss: $9.8 million ($0.11 per share) vs $11.6 million ($0.14 per share) prior year - 15% improvement • R&D expenses: $7.3 million vs $11.6 million prior year - 37% reduction in spending • G&A expenses: $3.5 million vs $2.7 million prior year - 30% increase • Cash position: $102.6 million at Sept 30, 2025 vs $132.2 million year earlier - 22% decline • Current cash balance: Over $120 million providing 3+ year runway at current burn rate • No revenue reported (clinical-stage biotechnology company)
Recent earnings history
Browse the calendar week| Date | Quarter | Report window | EPS est. | Revenue est. |
|---|---|---|---|---|
| May 26, 2026 | 2026-03-31 | Time not specified | -$0.07 | N/A |
| Feb 09, 2026 | Dec/2025 | Time not specified | -$0.10 | N/A |